The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery
Clinical Endocrinology · 2025
DOI: 10.1111/cen.15262 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von Xi Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academ…. Hauptthemen laut MEDLINE: Craniopharyngioma, Glucagon-Like Peptides, Obesity, Hypothalamic Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
Hypothalamic obesity, weight gain dominantly due to hypothalamic dysfunction, is a challenge for patients with craniopharyngioma surgery. Semaglutide, a long‐acting GLP‐1 receptor agonist, has shown promise in obesity management. However, the efficacy in this specific patient population remains underexplored.
Objective
This study aimed to evaluate the efficacy of semaglutide on weight reduction in patients with craniopharyngioma surgery.
Methods
A prospective clinical study was conducted involving 23 patients with obesity after craniopharyngioma surgery who attended the outpatient endocrinology department at Peking Union Medical College Hospital from March 2023 to October 2024. Patients were divided into a treatment group receiving semaglutide ( n = 14) and a control group undergoing lifestyle intervention alone ( n = 9). Parameters including weight, BMI, waist circumference, blood glucose and lipid profiles, were collected at baseline, 3 and 6 months of treatment.
Results
The treatment group showed a significant reduction in weight after 3 months (108.9 ± 20.9 kg vs. 100.8 ± 20.2 kg, p < 0.001) and after 6 months (108.9 ± 20.9 kg vs. 96.1 ± 23.1 kg, p < 0.001). Conversely, the control group experienced weight gain over the same periods. After 3 months, 64.3% of patients in the treatment group achieved weight loss greater than 5%. And after 6 months this rate increased to 90%.
Conclusion
Semaglutide demonstrated significant effects on weight loss in patients with hypothalamic obesity with craniopharyngioma surgery, providing a viable option for managing obesity in this population. Trial Registration: ChiCTR2400094933.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Department of Endocrinology, Loudi Central Hospital, Loudi, Hunan, China.
- Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Peking Union Medical College Hospital, Center of Excellence in Tissue Engineering o…
ORCID-Profile: Min Nie, Jiangfeng Mao, Xueyan Wu
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Wang, X., Ma, H., Wang, F., Long, H., Li, C., Nie, M., Han, Q., Mao, J., & Wu, X. (2025). The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery. Clinical Endocrinology. https://doi.org/10.1111/cen.15262
Vancouver
Wang X, Ma H, Wang F, Long H, Li C, Nie M, et al. The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery. Clinical Endocrinology. 2025. doi:10.1111/cen.15262
BibTeX
@article{Wang2025,
author = {Wang, Xi and Ma, Hailu and Wang, Fang and Long, Hongmei and Li, Chenyang and Nie, Min and Han, Qin and Mao, Jiangfeng and Wu, Xueyan},
title = {The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery},
journal = {Clinical Endocrinology},
year = {2025},
doi = {10.1111/cen.15262}
}
EUVIMED